Deutetrabenazine in india?

Deutetrabenazine (Austedo®) in India – What you need to know

| Topic | Information |
|-------|-------------|
| Drug & Indication | Deutetrabenazine (brand name Austedo®) is a deuterated analog of tetrabenazine, used to treat chorea associated with Huntington’s disease and tardive dyskinesia. |
| Regulatory status in India |

• As of the most recent updates (2024‑07), the Central Drugs Standard Control Organization (CDSCO) has not granted formal approval for Deutetrabenazine in India.
• There are no approved generic formulations available through the Indian market.

|
| Availability |

• In practice, the drug can sometimes be obtained via special import arrangements (e.g., under a “compassionate use” or “special access” scheme) through licensed pharmacies or hospitals that can import single‑patient drugs.
• Alternatively, some expatriates or Indian residents abroad may bring the medication back, but this involves strict customs and legal compliance.

|
| Typical dosing (when available) |

• Initial dose: 3 mg orally twice daily.
• Titrate upward (usually by 3 mg increments) every 3–7 days, aiming for a maintenance dose of 12 mg/day (e.g., 6 mg BID) as tolerated.
• Maximum recommended dose: 24 mg/day (12 mg BID) – but only under close neurologic supervision.

|
| Common side‑effects |

• Depression, anxiety, or mood changes (most serious).
• Somnolence, dizziness, fatigue.
• Nausea, dry mouth, constipation.
• Rarely, orthostatic hypotension or liver enzyme elevations.

|
| Precautions |

• Not suitable for patients with uncontrolled psychiatric disorders or severe liver disease.
• Should be used with caution in patients on other centrally acting CNS drugs.
• Pregnancy: Category B – but generally avoided unless benefits clearly outweigh risks.

|
| Cost (if imported) |

• Because it is a branded medication not sold through regular Indian pharmacies, cost can vary widely, often ranging from ₹15,000 to ₹25,000 per month, depending on importation fees, taxes, and courier charges.

|
| How to pursue access |

• Consult a neurologist or movement‑disorder specialist to confirm diagnosis and evaluate suitability.
• Ask the physician if they can apply for a “special import” or “compassionate use” application with the CDSCO. This may involve a detailed protocol and justification.
• Some hospitals in metro cities (Delhi, Mumbai, Bengaluru) have the infrastructure to file such requests on behalf of patients.

|
| Alternatives in India |

• Tetrabenazine (brand name Tetrabin®) – not deuterated; it is approved in India for chorea and has a longer track record.
• Other chorea‑modifying agents (e.g., antipsychotics like haloperidol, benzodiazepines, or deep brain stimulation) may be considered based on individual case and availability.

|

Bottom line

• Deutetrabenazine is not yet formally approved for use in India. If you believe you or a loved one may benefit, the first step is to discuss it with a specialist neurologist.
  
• Access requires a formal importation process or obtaining the drug through an international pharmacy with a valid prescription, both of which involve regulatory scrutiny and cost.
  
• Alternative treatments such as tetrabenazine or other symptomatic therapies are available and may be considered while the approval process for deutetrabenazine proceeds.
  
  If you need help finding a specialist or navigating the import procedure, let me know, and I can point you toward resources and patient‑support organizations that have experience with these pathways.